Integrative Biomedical Research
Integrative Biomedical Research (Journal of Angiotherapy) | Online ISSN 3068-6326
463
Citations
1.8m
Views
757
Articles
Volume 10 Number 1 2026
REVIEWS (Open Access)
Emerging CRISPR-Cas, Antibody, and Nanomedicine Strategies Against Antimicrobial Resistance in Critical Care
Ramji Gupta 1*, Vijay Jagdish Upadhye 2, Mitul Bhuptani 3
Integrative Biomedical Research 10 (1) 1-8 https://doi.org/10.25163/biomedical.10110908
Submitted: 12 February 2026 Revised: 06 April 2026 Accepted: 13 April 2026 Published: 15 April 2026
Abstract
Antimicrobial resistance (AMR) has become one of the defining threats to survival in intensive and neonatal intensive care units, where vulnerable hosts, invasive devices, and heavy empirical antibiotic exposure converge to select for multidrug- and extensively drug-resistant ESKAPE and non-aeruginosa Pseudomonas pathogens. We conducted a narrative-scoping synthesis of the peer-reviewed literature identified through targeted searches and, restricted to English-language articles addressing AMR mechanisms and next-generation, non-traditional therapeutics in critical care; reference lists were hand-searched, and findings were organized thematically rather than statistically pooled. Four convergent, non-traditional pillars emerged — programmable CRISPR-Cas and CRISPRi genomic tools, monoclonal antibodies and bioconjugates, antimicrobial and anticancer peptides (notably proline-rich peptides), and stimuli-responsive nanozymes and exosomal carriers — each capable of bypassing classical resistance mechanisms while, at least in preclinical models, sparing commensal microbiota. Persistent translational barriers include bedside diagnostic blindness to biofilm-embedded organisms, an unresolved neonatal and pediatric pharmacokinetic/pharmacodynamic void, and stewardship frameworks that still largely ignore the human resistome. Bridging bench-to-bedside gaps will require standardized biofilm models, dedicated pediatric PK/PD trials, artificial-intelligence-assisted therapeutic design, and microbiome-conscious stewardship, particularly given resource disparities across low- and middle-income settings.
Keywords: antimicrobial resistance; critical care; CRISPR-Cas antimicrobials; monoclonal antibodies; antimicrobial peptides; nanozymes; antimicrobial stewardship
References
Abdullah, S., Thiab, S., Omar, A., Barakat, M., & Abdulhameed, A. S. (2026). Nano-enabled glycopeptide strategies against antimicrobial resistance: Immunological interfaces, exosomal delivery, and analytical frontiers. Food Hydrocolloids for Health, 9, Article 100290. https://doi.org/10.1016/j.fhfh.2026.100290
Abudayyeh, O. O., Gootenberg, J. S., Konermann, S., Joung, J., Slaymaker, I. M., Cox, D. B., & Zhang, F. (2016). C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science, 353(6299), aaf5573. https://doi.org/10.1126/science.aaf5573
Agha, A. S. A., Al-Samydai, A., & Aburjai, T. (2025). New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14. Heliyon, 11(2), e41392. https://doi.org/10.1016/j.heliyon.2025.e41392
Allemailem, K. S. (2024). Recent advances in understanding the molecular mechanisms of multidrug resistance and novel approaches of CRISPR/Cas9-based genome-editing to combat this health emergency. International Journal of Nanomedicine, 19, 1125–1143. https://doi.org/10.2147/IJN.S441111
Aquino-Jarquin, G. (2019). CRISPR-Cas14 is now part of the artillery for gene editing and molecular diagnostic. Nanomedicine: Nanotechnology, Biology and Medicine, 18, 428–431. https://doi.org/10.1016/j.nano.2019.03.003
Aresta, A. M., Signorile, G. S., Clemente, A., De Vietro, N., & Zambonin, C. (2026). Oral cavity antibacterial discovery pipeline driven by advanced analytical techniques. Molecules, 31(10), Article 02804. https://doi.org/10.3390/molecules31102804
Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., Fischetti, V. A., & Marraffini, L. A. (2014). Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nature Biotechnology, 32(11), 1146–1150. https://doi.org/10.1038/nbt.3043
Blazejczyk, I., Daniluk, T., Toczylowski, K., Gorbacz-Kononczuk, J., Wnorowska, U., Bucki, R., & Piktel, E. (2026). Antimicrobial peptides in cervical carcinogenesis: Dual roles in tumor progression and emerging therapeutic strategies. Biomedicine & Pharmacotherapy, 194, Article 118928. https://doi.org/10.1016/j.biopha.2025.118928
Chen, J. S., Ma, E., Harrington, L. B., Da Costa, M., Tian, X., Palefsky, J. M., & Doudna, J. A. (2018). CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science, 360(6387), 436–439. https://doi.org/10.1126/science.aar6245
Chen, L., Xing, Y., Lei, Q., Chen, Z., Zou, K., Quan, Z., Qing, J., Liu, R., & Yang, R. (2021). A glucose-powered activatable nanozyme breaking pH and H2O2 limitations for treating diabetic infections. Angewandte Chemie International Edition, 60(44), 23534–23539. https://doi.org/10.1002/anie.202107712
Chen, S., Cao, H., Xu, Z., Huang, J., Liu, Z., Li, T., & Zhang, Y. (2023). A type IF CRISPRi system unveils the novel role of CzcR in modulating multidrug resistance of Pseudomonas aeruginosa. Microbiology Spectrum, 11(5), e01123-23. https://doi.org/10.1128/spectrum.01123-23
Citorik, R. J., Mimee, M., & Lu, T. K. (2014). Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nature Biotechnology, 32(11), 1141–1145. https://doi.org/10.1038/nbt.3043
Csörgo, B., León, L. M., Chau-Ly, I. J., Vasquez-Rifo, A., Berry, J. D., Mahendra, C., Crawford, E. D., Lewis, J. D., & Bondy-Denomy, J. (2020). A compact Cascade–Cas3 system for targeted genome engineering. Nature Methods, 17(12), 1183–1190. https://doi.org/10.1038/s41598-020-73796-5
De Oliveira, D. M., Forde, B. M., Kidd, T. J., Harris, P. N., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020). Antimicrobial resistance in ESKAPE pathogens. Clinical Microbiology Reviews, 33(3), e00181-19. https://doi.org/10.1128/CMR.00181-19
Elbehiry, A., & Marzouk, E. (2026a). Helicobacter pylori eradication in the era of antibiotic resistance: From universal regimens to precision-guided management. Antibiotics, 15, Article 00673.
Elbehiry, A., & Marzouk, E. (2026b). Beyond resistance genes: Pseudomonas aeruginosa as a complex adaptive system driving persistence, evolution, and antimicrobial resistance. Life, 16, Article 01163.
Feng, S., Wang, Z., Wang, Y., Mei, L., & Wang, Z. (2025). Harnessing nanozymes as next-generation antimicrobial agents: From mechanisms to therapeutic strategies. Materials Today Bio, 35, Article 102499. https://doi.org/10.1016/j.mtbio.2025.102499
Feng, S., Wang, Z., Zhang, Y., Mei, L., & Wang, Z. (2026). Corrigendum to “Harnessing nanozymes as next-generation antimicrobial agents.” Materials Today Bio, 37, Article 102812.
Gholamian, S., Baghaee, P., & Doroudian, M. (2025). Nanotechnology in gene editing: Pioneering CRISPR-Cas delivery systems to tackle antibiotic resistance. Advanced Therapeutics, 8(3), Article 2400412. https://doi.org/10.1002/adtp.2400412
Gholizadeh, P., Köse, S., Dao, S., Ganbarov, K., Tanomand, A., Dal, T., Aghazadeh, M., Ganbarov, K., & Kafil, H. S. (2020). How CRISPR-Cas system could be used to combat antimicrobial resistance. Infectious Drug Resistance, 13, 1111–1121. https://doi.org/10.2147/IDR.S247271
Hadi, J., Rapp, D., Dhawan, S., Gupta, S. K., Gupta, T. B., & Brightwell, G. (2023). Molecular detection and characterization of foodborne bacteria: Recent progresses and remaining challenges. Comprehensive Reviews in Food Science and Food Safety, 22(3), 2433–2464. https://doi.org/10.1111/1541-4337.13147
Hamilton, T. A., Pellegrino, G. M., Therrien, J. A., Ham, D. T., Bartlett, P. C., Karas, B. J., & Csörgo, B. (2019). Efficient inter-species conjugative transfer of a CRISPR nuclease for targeted bacterial killing. Nature Communications, 10(1), 4544. https://doi.org/10.1038/s41467-019-12444-y
Harrington, L. B., Burstein, D., Chen, J. S., Paez-Espino, D., Ma, E., Witte, I. P., Cofsky, J. C., Kyrpides, N. C., Banfield, J. F., & Doudna, J. A. (2018). Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. Science, 362(6416), 839–842. https://doi.org/10.1126/science.aav9710
Hubert, P., Herman, L., Maillard, J. H., Caberg, A., Nikkels, G., Pierard, P., & Delvenne, P. (2007). Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo. The FASEB Journal, 21(11), 2765–2775. https://doi.org/10.1096/fj.06-8152fjs
Hubert, P., Herman, L., Roncarati, C., Maillard, V., Renoux, S., Demoulin, M., & Herfs, M. (2014). Altered α-defensin 5 expression in cervical squamocolumnar junction: Implication in the formation of a viral/tumour-permissive microenvironment. The Journal of Pathology, 234(4), 464–477. https://doi.org/10.1002/path.4414
Idakwoji, P. A., Fadipe, D. E., Aliyu, A. O., Banwo, F. M., Nwafor, I. P., Isiah, Z., & Umari, M. M. (2026). Human microbiome-driven antimicrobial resistance: Biological mechanisms, pharmacological considerations and next-generation therapeutic prospects. Letters in Drug Design & Discovery, 23, Article 100420.
Jiang, S., Xie, D., Hu, Z., Song, H., Tang, P., Jin, Y., & Fu, Q. (2024). Enhanced diabetic wound healing with injectable hydrogel containing self-assembling nanozymes. Journal of Controlled Release, 372, 265–280. https://doi.org/10.1016/j.jconrel.2024.06.040
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816–821. https://doi.org/10.1126/science.1225829
Khosrojerdi, M., Hashemi, S. A., Besharati, R., Haghbin, A., & Azimian, A. (2026). CRISPR-Cas systems as precision antimicrobials: Reversing the tide of antimicrobial resistance. Virus Research, 371, Article 199782. https://doi.org/10.1016/j.virusres.2026.199782
Kiga, K., Tan, X.-E., Ibarra-Chávez, R., Watanabe, S., Aiba, Y., Sato’o, Y., & Hayashi, T. (2020). Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. Nature Communications, 11(1), 2934. https://doi.org/10.1038/s41467-020-16731-6
Kiro, R., Shitrit, D., & Qimron, U. (2014). Efficient engineering of a bacteriophage genome using the type IE CRISPR-Cas system. RNA Biology, 11(1), 42–44. https://doi.org/10.4161/rna.27714
Krizsan, A., Volke, D., Weinert, S., Sträter, N., Knappe, D., & Hoffmann, R. (2014). Insect-derived proline-rich antimicrobial peptides kill bacteria by inhibiting bacterial protein translation at the 70S ribosome. Angewandte Chemie International Edition, 53, 12236–12239. https://doi.org/10.1002/anie.201407145
Kuo, S.-F., Huang, T.-Y., Lee, C.-Y., Chen, F.-J., & Lee, C.-H. (2026). CRISPR-Cas9-mediated elimination of plasmid-borne carbapenemase genes restores ertapenem susceptibility in clinical Klebsiella pneumoniae isolates. Biomedical Journal, Article 100966. https://doi.org/10.1016/j.bj.2026.100966
Li, W., Wang, W., Chen, B., Sun, M., Ma, X., Wang, L., & Zhou, M. (2026). Balancing cationicity and hydrophobicity in Dermaseptin-A4 generates a selective antimicrobial peptide with enhanced therapeutic potential. Antibiotics, 15, Article 00784. https://doi.org/10.3390/antibiotics15080784
Lin, Z., You, Q., Zhu, H., Lao, Z., Lao, J., Li, X., & Nie, M. (2026). Strategies to enhance the efficacy and clinical translation of antimicrobial photodynamic therapy. Antibiotics, 15, Article 00748. https://doi.org/10.3390/antibiotics15080748
Lucero-Prisno III, D. E., Okesanya, O. J., Agboola, A. O., Adebayo, U. O., Adigun, O. A., Ahmed, M. M., & Olawade, D. B. (2025). Emerging technologies and innovative approaches to combat antimicrobial resistance: A narrative review of next-generation therapeutic strategies. Next Bioengineering, 1, Article 100003. https://doi.org/10.1016/j.nxbio.2025.100003
Maghiar, L., Maghiar, P. B., Pop, O., Mitran, A. M., Muresan, M. M., Neam?u, A. A., & Dehelean, C. A. (2026). A comprehensive review of antimicrobial peptides and smart biomaterials in chronic wound therapy: Overcoming biofilms, resistance, and translational barriers. International Journal of Molecular Sciences, 27, Article 05955. https://doi.org/10.3390/ijms27115955
Mangano, K., Klepacki, D., Ohanmu, I., Baliga, C., Huang, W., Brakel, A., & Mankin, A. (2023). Inhibition of translation termination by the antimicrobial peptide Drosocin. Nature Chemical Biology, 19, 1082–1090. https://doi.org/10.1038/s41589-023-01300-x
Marino, A., Stracquadanio, S., Cosentino, F., Coco, M., La Via, L., Franzò, A., & Maniaci, A. (2026). Beyond the usual suspects: Emerging Pseudomonas species in clinical and environmental niches. International Journal of Molecular Sciences, 27, Article 06210.
Mattiuzzo, M., Bandiera, A., Gennaro, R., Benincasa, M., Pacor, S., Antcheva, N., & Scocchi, M. (2007). Role of the Escherichia coli SbmA in the antimicrobial activity of proline-rich peptides. Molecular Microbiology, 66, 151–163. https://doi.org/10.1111/j.1365-2958.2007.05903.x
Murray, C. J., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., et al. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., et al. (2024). Global burden of bacterial antimicrobial resistance 1990–2021: A systematic analysis with forecasts to 2050. The Lancet, 404(10459), 1199–1226. https://doi.org/10.1016/S0140-6736(24)01867-1
Noble, C., Olejarz, J., Esvelt, K. M., Church, G. M., & Nowak, M. A. (2017). Evolutionary dynamics of CRISPR gene drives. Science Advances, 3(4), e1601964. https://doi.org/10.1126/sciadv.1601964
Ntais, C., & Chatziprodromidou, I. P. (2026). Antimicrobial resistance as a global public health challenge: Epidemiological burden, bioethical dimensions and emerging therapeutic strategies. Infectious Disease Reports, 18, Article 00070.
Oechslin, F. (2018). Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses, 10(7), 351. https://doi.org/10.3390/v10070351
O’Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance.
Papageorgiou, D., & Akinosoglou, K. (2026). Antimicrobial resistance in major Gram-positive pathogens: Beyond the vancomycin border. Antibiotics, 15, Article 00780.
Papanikolaou, N. G., Giapros, V., Papaioannou, E., Nikolaou, A. I., Baltogianni, M., Balomenou, F., & Dermitzaki, N. (2026). Evolution of antimicrobial resistance in neonatal sepsis: A narrative review. Antibiotics, 15, Article 00682.
Patel, W., Tailhades, J., O’Brien-Simpson, N. M., Separovic, F., Otvos Jr, L., Hossain, M. A., & Wade, J. D. (2026). Proline-rich antimicrobial peptides: Structural and functional characteristics of Next Generation Therapeutics. Current Opinion in Chemical Biology, 93, Article 102699. https://doi.org/10.1016/j.cbpa.2026.102699
Pintilei, P. S., Binaymotlagh, R., Haghighi, F. H., Chronopoulou, L., & Palocci, C. (2026). Functional liposomal nanocarriers for the treatment of antimicrobial-resistant and biofilm-associated ocular infections. Macromolecular Materials and Engineering, 6, Article 00056. https://doi.org/10.1002/mame.202600056
Pursey, E., & Gaze, W. H. (2022). CRISPR-Cas antimicrobials: Challenges and future prospects. Nature Reviews Microbiology, 20(7), 383–397. https://doi.org/10.1038/s41579-022-00705-0
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 152(5), 1173–1183. https://doi.org/10.1016/j.cell.2013.02.022
Ridelfi, M., Fonseca, V. Z. G., Sala, C., & Rappuoli, R. (2026). Human antibodies as emerging drugs for antimicrobial resistance. Trends in Immunology, 24, 1–15.
Saffari Natanzi, A., Poudineh, M., Karimi, E., Khaledi, A., & Haddad Kashani, H. (2025). Innovative approaches to combat antibiotic resistance: Integrating CRISPR/Cas9 and nanoparticles against biofilm-driven infections. BMC Medicine, 23(1), 486. https://doi.org/10.1186/s12916-025-04323-4
Sheng, H., Wu, S., Xue, Y., Zhao, W., Caplan, A. B., Hovde, C. J., & Qimron, U. (2023). Engineering conjugative CRISPR-Cas9 systems for the targeted control of enteric pathogens and antibiotic resistance. PLoS One, 18(9), e0291520. https://doi.org/10.1371/journal.pone.0291520
Sinkunas, T., Gasiunas, G., Fremaux, C., Barrangou, R., Horvath, P., & Siksnys, V. (2011). Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system. EMBO Journal, 30(7), 1335–1342. https://doi.org/10.1038/emboj.2011.41
Su, Y., Ding, M., Dong, H., Dong, Y., Hu, Y., Yang, D., & Shao, J. (2022). Recent advances in nanozymes for combating bacterial infection. Materials Chemistry Frontiers, 6(18), 2596–2609. https://doi.org/10.1039/D2QM00511E
Thery, C., Witwer, K. W., & Aikawa, E. (2022). Minimal information for studies of extracellular vesicles 2022 (MISEV2022). Journal of Extracellular Vesicles, 11(8), e12217. https://doi.org/10.1002/jev2.12217
Tian, T., Li, X., Hua, Z., Ma, J., Wu, X., Liu, Z., & Cui, Z. (2017). S100A7 promotes the migration, invasion and metastasis of human cervical cancer cells through epithelial–mesenchymal transition. Oncotarget, 8(15), 24964–24978. https://doi.org/10.18632/oncotarget.15641
Umumararungu, T., Gahamanyi, N., Mukiza, J., Habarurema, G., Katandula, J., Rugamba, A., & Otvos, L. (2024). Proline, a unique amino acid whose polymer, polyproline II helix, and its analogues are involved in many biological processes: A review. Amino Acids, 56, 50. https://doi.org/10.1007/s00726-024-03410-9
Wan, F., Draz, M. S., Gu, M., Yu, W., Ruan, Z., & Luo, Q. (2021). Novel strategy to combat antibiotic resistance: A sight into the combination of CRISPR/Cas9 and nanoparticles. Pharmaceutics, 13(3), 352. https://doi.org/10.3390/pharmaceutics13030352
Wang, D., He, J., Dong, J., Wu, S., Liu, S., He, T., & Xu, T. (2021). UM-6 induces autophagy and apoptosis via the Hippo-YAP signaling pathway in cervical cancer. Cancer Letters, 519, 2–19. https://doi.org/10.1016/j.canlet.2021.06.012
Wei, T., Pan, T., Peng, X., Zhang, M., Guo, R., Guo, Y., & Zhang, S. (2024). Janus liposozyme for the modulation of redox and immune homeostasis in infected diabetic wounds. Nature Nanotechnology, 19(8), 1178–1189. https://doi.org/10.1038/s41565-024-01660-y
Xu, D., Zhang, B., Liao, C., Zhang, W., Wang, W., Chang, Y., & Shao, Y. (2016). Human beta-defensin 3 contributes to the carcinogenesis of cervical cancer via activation of NF-κB signaling. Oncotarget, 7(46), 75902–75913. https://doi.org/10.18632/oncotarget.12215
Yang, X., Shi, G., Guo, J., Wang, C., & He, Y. (2018). Exosome-encapsulated antibiotic against intracellular infections of methicillin-resistant Staphylococcus aureus. International Journal of Nanomedicine, 13, 8095–8104. https://doi.org/10.2147/IJN.S180954
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., & Zhang, F. (2015). Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell, 163(3), 759–771. https://doi.org/10.1016/j.cell.2015.09.038